Floatz logo

PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493

Locally Advanced Ureter Urothelial Carcinoma

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Locally Advanced Ureter Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Alliance for Clinical Trials in Oncology
Phase 3BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
Atezolizumab
Alliance for Clinical Trials in Oncology
Phase 3B

View all 20 →

Same molecule, other indications

PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493 is also rated in:

neoplasmDormant
B
Indicative ·
60 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
lymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →